Chairman: Timothy Wollaeger

Mr. Wollaeger has more than 30 years of experience in the medical products and biotechnology fields in both corporate management and venture capital. He joined Sanderling Ventures as a Managing Director in 2002, opened the firm's San Diego office, and serves on the Board of Directors for several Sanderling portfolio companies. He is currently Chairman of the Board of Directors for Sotera Wireless and became Chairman of the Board for Naviscan in November of 2012. Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. Mr. Wollaeger also helped found Columbia Hospital Corporation in 1990. In 1986, Mr. Wollaeger became a founding General Partner of Biovest, where he helped found Pyxis, Biosite, Amylin Pharmaceuticals (NASDAQ: AMLN) and Vical (NASDAQ: VICL). All four of these companies became public. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from Stanford in 1971.

President & CEO: Paul J. Mirabella

Mr. Mirabella has over 35 years of diagnostic imaging experience and was previously with GE Healthcare, where he held leadership roles in technology, marketing and global business management in diagnostic imaging sales and services. Mr. Mirabella holds four patents in CT and has participated in a variety of successful global product launches. Prior to joining Naviscan, he was President and CEO of Global Diagnostic Imaging, while retaining responsibility for the commercial leadership of sales, marketing, and services in the Americas. Mr. Mirabella obtained degrees in Aerospace Engineering and Applied Mechanics from Polytechnic Institute in New York and a Masters in Mechanical Engineering from the University of Central Florida. He is a graduate of the GE Business Management Program accredited by the University of Wisconsin-Whitewater.

Director: Timothy Mills, PhD

With over 25 years of experience in biomedical research, corporate management and venture investing, Dr. Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. Sanderling portfolio companies he previously served include Stereotaxis and Stentor, acquired by Royal Philips Electronics. Additionally, he is Chairman and CEO of Torax Medical, Taligen Therapeutics, Pulsar Vascular and Theregen and is a Director for CardioNet, Novostent, InfraReDx, and Triage Wireless. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics. Dr. Mills received his PhD in bioengineering from the University of California, Berkeley & San Francisco School of Medicine.

Director: Gina Dubbé

As a Managing Partner and co-founder of Walker Ventures, Ms. Dubbé is responsible for the selection and management of a $100M investment portfolio of early stage companies. Prior to the founding of Walker Ventures, Ms. Dubbé was a key part of the management team that led the IPO and sale of Trusted Information Systems. Ms. Dubbe has held key sales and engineering management positions with ORACLE Corporation, PRC Corporation, Interleaf Corporation and Arinc Research. Ms. Dubbé is a Licensed Professional Engineer with a Master's degree in engineering from George Washington University.

Director: André Cheng, MD, PhD

Dr. Cheng is the Senior Vice President for Healthcare at Height Analytics. He has extensive clinical and business experience related to reimbursement in the medical device industry. He has served as the Vice President of Medical Affairs and Reimbursement at Acclarent, Inc. After acquisition by Ethicon, Inc., a Johnson & Johnson company, he served as Worldwide vice President of Health Economics and Reimbursement. Prior to this, he was a Managing Partner for The Advisory Board Company. Dr. Cheng is a graduate of the Johns Hopkins School of Medicine and holds a PhD in Clinical Investigations and Healthcare Economics from the Johns Hopkins School of Public Health. 

Director: Ronald Schilling, PhD

Dr. Schilling has over 40 years of operating and general management experience in the medical device and technology industries. Most recently, Dr. Schilling was a General Partner at Mi3 Venture Partners, a venture capital investment fund for the imaging-related sector of the healthcare industry. He is President of RBS Consulting Inc., a firm specializing in strategic planning for biomedical imaging companies and not-for-profit organizations. Dr. Schilling has held various executive positions at Toshiba America Medical Systems, Diasonics, and General Electric Medical Systems. Dr. Schilling holds a PhD in electrical engineering from Polytechnic Institute of New York.

Secretary: Thomas Coll

Mr. Coll is a partner in the Cooley Godward Kronish Business department. He joined the firm in 1989, practicing in the San Francisco office until moving to San Diego as a founding member of that office in November 1991. Mr. Coll received a J.D. from the University of California, Berkeley School of Law, where he was a member of the Order of the Coif. He is a member of the State Bar of California, the American Bar Association and the San Diego County Bar Association. Mr. Coll was selected for the 2006 edition of The Best Lawyers in America for the Leveraged Buyouts and Private Equity Law category.